Divyam Pharmaceuticals

• Combination Chemotherapy Agent
  This oral formulation combines Tegafur (a prodrug of 5-FU), Gimeracil (an enzyme inhibitor that prolongs 5-FU activity), and Oteracil (reduces gastrointestinal toxicity), enhancing efficacy while minimizing side effects.

• Used in Solid Tumors
  Commonly used to treat gastric cancer, colorectal cancer, pancreatic cancer, and head and neck cancers, especially in advanced or metastatic stages.

• Oral Administration
  Convenient capsule form allows for outpatient chemotherapy. The dosage and schedule depend on body surface area and the specific cancer being treated.

• Side Effect Profile
  Side effects may include nausea, diarrhea, hand-foot syndrome, fatigue, and myelosuppression. Regular monitoring of blood counts and organ function is necessary.

Additional Information:

• Delivery Time: 24 hrs
• Packaging Details: As per customer required

• Anti-Fibrotic and Anti-Angiogenic Agent: Nintedanib is used primarily for treating idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ILD, and other progressive fibrosing interstitial lung diseases.

• Tyrosine Kinase Inhibitor (TKI): It works by blocking multiple growth factor receptors (like VEGFR, FGFR, and PDGFR), slowing down the progression of lung fibrosis.

• Oral Administration: Taken orally, usually twice daily, with food to reduce gastrointestinal side effects. Available in soft gelatin capsule form for easier swallowing and faster absorption.

• Common Side Effects: Diarrhea, nausea, liver enzyme elevation, and reduced appetite are the most frequently reported side effects; regular liver function monitoring is recommended.